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26901
The genetics of early-stage melanoma in a veteran population
Kevin Cheung, BS, University of Iowa Carver College of Medicine, Iowa
City, Iowa; Aaron D. Bossler, MD, PhD, Department of Pathology,
University of Iowa Hospitals and Clinics, Iowa City, Iowa; Sarah L.
Mott, MS, Holden Comprehensive Cancer Center, University of Iowa Hospitals
and Clinics, Iowa City, Iowa; Megan Aadland, MPH, Department of Biostatistics,
University of Iowa College of Public Health, Iowa City, Iowa; Julie McKillip, RN,
BSN, Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa
City, Iowa; Brian L. Swick, MD, Department of Dermatology, University of Iowa
Hospitals and Clinics, Iowa City, Iowa; Jennifer G. Powers, MD, Department of
Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
Military personnel are at increased risk for melanoma compared with the general
population. To improve understanding of the genetic signature of early-stage
melanomas in veterans, mutation profiling using next-generation sequencing
(NGS) was performed on melanoma tissue samples from patients at the Iowa City
VAMC and analyzed for hotspot mutations. Genetic analysis identified BRAF (36%),
TP53 (26%), NRAS (19%), CDKN2A (11%), KIT (8%), and BAP1 (7%) mutations with
the highest prevalence. Although common variants in BRAF were detected at lower
rates than what is reported for the general population, 55% of cases showed
activating mutations in the RAS/RAF pathways. Variants in TP53 and KIT were
detected at higher rates than in the general population. Patients with prior history of
melanoma were at significantly higher odds of having TP53 mutation (OR ¼ 2.67, P
¼ .04). This finding suggests that TP53 may indicate alternative exposures in the
military population and may be used to help identify veterans at particularly
increased risk of recurrence. In conclusion, this study provides new information
regarding both genetics of melanoma in a veteran population and early-stage tumors.
Ultimately, these findings should influence how we educate, screen, and treat
melanoma in veterans and active military personnel and pave the way for continued
research to identify exposures and risk factors unique to this population.
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Ustekinumab-induced myositis: A case series
Nneamaka Ezekwe, MD, Department of Dermatology, Henry Ford
Health Systems; Josee Smith, BS, School of Medicine, Wayne State
University; Aunna Pourang, MD, Department of Dermatology, Henry
Ford Health Systems; Iltefat Hamzavi, MD, Department of Dermatology, Henry
Ford Health Systems
Ustekinumab (UST) is a monoclonal antibody that blocks proinflammatory
cytokines IL-12 and IL-23. Off-label use of UST has shown promising results for
moderate to severe hidradenitis suppurativa (HS) in patients who have failed to
respond to or unable to tolerate adalimumab, the only Food and Drug
Administration (FDA) approved treatment for HS. Previously, myositis has not
been reported as an adverse effect of UST. We present two patients with poorly
controlled HS who experienced new onset myositis shortly after beginning
treatment with UST. Abnormal electromyography (EMG) demonstrated myopathic
appearing motor units in the bilateral biceps in patient 1. Creatinine kinase was
elevated greater than three times normal in patient 1, and normal in patient 2.
Patient 2 had marked reduction in ambulation requiring use of a cane. Both patients
experienced a sequela of symptoms such as generalized muscle weakness, muscle
swelling with warmth to the areas, and myalgias with improvement of symptoms
shortly after discontinuation of UST. A proposed mechanism may be related to the
overexpression of IL-12 and IL-23 secondary to UST’s receptor blockade. IL-12 can
initiate IL-32 production, a cytokine that has been shown to be overexpressed in
HS.3 Il-32 induces the production of IFNy and IL-17, byproducts of TH1 and TH17
helper cells which have been implicated in autoimmune myositis. As the use of UST
increases in HS patients, it is important for clinicians to consider the potential risk of
drug-induced myositis. Long-term clinical surveillance is needed to evaluate the
significance and frequency of this occurrence.
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26908
The safety of isotretinoin treatment in patients with peanut or
cashew allergies—A case series
Noelle Lemons, BS, West Virginia University School of Medicine;
Ahmed Yousaf, BA, Department of Dermatology, West Virginia
University; Zachary Zinn, MD, Department of Dermatology, West Virginia
University
Background: The gold standard treatment for nodulocystic acne vulgaris, isotretinoin, is contraindicated in patients with a soy allergy as its capsule contains
hydrogenated soybean oil. This has raised concern for its use in patients with peanut
and cashew allergies due to the potential for cross-reactivity. Cashew allergy has
been reported to confer a greater risk of cross-reactivity to soy, resulting in rare
allergic reactions to isotretinoin. This case series sought to further evaluate the
safety of isotretinoin use in eleven patients with a history of peanut or cashew
allergy.
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Effectiveness of guselkumab among patients with moderate-tosevere plaque psoriasis in the Corrona Psoriasis Registry
April W. Armstrong, MD, MPH, University of Southern California, Los
Angeles, CA & Harvard Medical School, Boston, MA; Kristina CallisDuffin, MD, MS, University of Utah, Salt Lake City, UT; Timothy Fitzgerald, PhD,
Janssen Scientific Affairs LLC, Horsham, PA; Amanda Teeple, Janssen Scientific
Affairs LLC, Horsham, PA; Jonathan Uy, MD, Janssen Scientific Affairs LLC,
Horsham, PA; Mobolaji Olurinde, MD, PhD, Janssen Scientific Affairs LLC,
Horsham, PA; Katelyn Rowland, Janssen Scientific Affairs LLC, Horsham, PA;
Robert R. McLean, DSc, MPH, Corrona, LLC, Waltham, MA; Lin Guo, PhD,
Corrona, LLC, Waltham, MA; Ying Shan, MD, Corrona, LLC, Waltham, MA; Abby
S. Van Voorhees, MD, Eastern Virginia Medical School, Norfolk, VA
Background: Guselkumab is an IL-23 inhibitor approved for the treatment of
moderate-to-severe plaque psoriasis (PsO). To date, there is limited information on
the effect of persistent guselkumab treatment on disease severity in a real-world
setting.
Objective: To assess the effectiveness of guselkumab following 9-12 months of
persistent use among patients with moderate-to-severe plaque PsO.

Methods: Five males and six females were identified with a history of peanut or
cashew allergy and treatment for acne vulgaris with isotretinoin between January
2010 and June 2020. Ten patients had a history of peanut allergy; one of these
patients had a coexisting cashew allergy. One patient had a history of tree nut allergy
including cashews.
Results: Reported reactions to peanut or cashew included urticaria, pruritis, edema,
dysphagia, and anaphylaxis independent of isotretinoin use. Four patients reported
positive immunoglobulin E response to peanut. One patient had a positive skin prick
test for peanut. All eleven patients tolerated isotretinoin without evidence of allergic
reaction.
Conclusion: Avoidance of isotretinoin in patients with peanut allergies is likely
unnecessary. Additional studies are needed to assess isotretinoin’s safety in patients
with cashew allergies.

Methods: This study included 113 adult plaque PsO patients enrolled in the Corrona
PsO Registry between July 2017 and March 2020 with an Investigator’s Global
Assessment (IGA) score $3 and Body Surface area (BSA) $10%, who initiated
guselkumab at or after enrollment, and had a follow-up visit after 9-12 months of
persistent treatment with guselkumab. Baseline demographics, disease characteristics, and treatment history were collected; response rates and mean change in
disease activity between the index and follow-up visits were calculated.
Results: Guselkumab users were mean age 50 years, 40% female, 70% white, and 59%
had a body mass index (BMI) $30 kg/m2. Comorbidities included cardiovascular
disease (10%), hypertension (35%), hyperlipidemia (20%), diabetes (19%), and
depression (23%). The average PsO duration was 17.5 years, and 66% of patients had
previously used at least one biologic. The mean IGA was 3.3 at baseline. At followup, 62% (95% CI: 53, 71) of patients achieved an IGA 0/1, and 40% (95% CI: 31, 49)
achieved an IGA of 0.
Conclusion: Real-world patients with moderate-to-severe plaque PsO treated
persistently with guselkumab for 9-12 months demonstrated improvement in PsO
severity.
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